CASTLE BIOSCIENCES, INC. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings
CASTLE BIOSCIENCES, INC. (CSTL) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings of -$18.29 million for the 12-month period ending 2022-12-31, per its 10-K filed 2023-02-28.
Discontinued › Income Statement › Other Income
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings · last filed 2023-02-28
- CASTLE BIOSCIENCES, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2022-12-31 was -$300.00K.
- CASTLE BIOSCIENCES, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2022-09-30 was -$151.00K.
- CASTLE BIOSCIENCES, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2022-06-30 was -$20.40M.
- CASTLE BIOSCIENCES, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2022-03-31 was $2.56M.
- CASTLE BIOSCIENCES, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2022 was -$18.29M.
- CASTLE BIOSCIENCES, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2021 was $0.00.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 12 month |
|---|---|---|---|---|
| 2022-12-31 | -$300.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | -$451.00K derived: sum of 2 quarters · filed 2023-02-28 | -$20.85M derived: sum of 3 quarters · filed 2023-02-28 | -$18.29M 10-K · filed 2023-02-28 |
| 2022-09-30 | -$151.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | -$20.55M derived: sum of 2 quarters · filed 2022-11-02 | -$17.99M 10-Q · filed 2022-11-02 | |
| 2022-06-30 | -$20.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | -$17.84M 10-Q · filed 2022-08-08 | ||
| 2022-03-31 | $2.56M 10-Q · filed 2022-05-09 | |||
| 2021-12-31 | $0.00 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Personalis, Inc. (PSNL) | United States | $1.769B | -13.30 |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Fortrea Holdings Inc. (FTRE) | United States | $1.903B | -19.43 |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B |